Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC14396 Ponatinib (AP24534) Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  3. GC52104 Ponatinib (hydrochloride) An inhibitor of native and mutant Bcr-Abl Ponatinib (hydrochloride) Chemical Structure
  4. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8 Chemical Structure
  5. GC69728 Ponezumab

    Ponezumab (PF-04360365) is a humanized monoclonal antibody against amyloid beta protein of the IgG2 class. Ponezumab can reduce Aβ levels in the central nervous system and improve performance in various learning and memory models in mice. Ponezumab can be used for research on Alzheimer's disease.

     Ponezumab Chemical Structure
  6. GC17916 Poziotinib A irreversible pan-HER inhibitor Poziotinib Chemical Structure
  7. GC17990 PP 1 Potent, selective Src family tyrosine kinase inhibitor PP 1 Chemical Structure
  8. GC10344 PP 2 (AG 1879) A selective inhibitor of Src tyrosine kinases PP 2 (AG 1879) Chemical Structure
  9. GC13797 PP 3 Negative control for the Src kinase inhibitor PP 2 PP 3 Chemical Structure
  10. GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases PP121 Chemical Structure
  11. GC32835 PP58 PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values. PP58 Chemical Structure
  12. GC17137 pp60 c-src (521-533) (phosphorylated) Peptide corresponding to the pp60c-src carboxy terminal regulatory domain pp60 c-src (521-533) (phosphorylated) Chemical Structure
  13. GC12779 PPY A Abl kinases inhibitor PPY A Chemical Structure
  14. GC16991 PQ 401 IGF1R inhibitor,potent and cell-permeable PQ 401 Chemical Structure
  15. GC31780 Pralsetinib (Blu667) Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (Blu667) (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively. Pralsetinib (Blu667) Chemical Structure
  16. GC32802 PRN1371 An irreversible pan-FGFR inhibitor PRN1371 Chemical Structure
  17. GC30502 PRN694

    PRN694 is an irreversible, highly selective and potent covalent interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) dual inhibitor with IC50s of 0.3 nM and 1.4 nM, respectively.

     PRN694 Chemical Structure
  18. GC46208 Propentofylline A xanthine derivative and neuroprotective agent Propentofylline Chemical Structure
  19. GC36985 PROTAC FAK degrader 1 PROTAC FAK degrader 1 is a selective and potent von Hippel-Lindau-based focal adhesion kinase (FAK) degrader with an IC50 of 6.5 nM, DC50 of 3 nM. PROTAC FAK degrader 1 Chemical Structure
  20. GC65555 PROTAC FLT-3 degrader 1 PROTAC FLT-3 degrader 1 is a von Hippel-Lindau-based PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction. PROTAC FLT-3 degrader 1 Chemical Structure
  21. GC62197 PROTAC IRAK4 degrader-1 PROTAC IRAK4 degrader-1 is a Cereblon-based PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4) degrader extracted from patent US20190192668A1 Compound I-210, makes 20-50%, and >50% IRAK4 degradation at 0.01, 0.1, and 1 μM in OCI-LY-10 cells, respectively. PROTAC IRAK4 degrader-1 Chemical Structure
  22. GC69769 Protein kinase inhibitor 1 hydrochloride

    Protein kinase inhibitor 1 hydrochloride is an effective inhibitor of HIPK2, with IC50 values of 136 and 74 nM for HIPK1 and HIPK2 respectively, and a Kd value of 9.5 nM for HIPK2.

     Protein kinase inhibitor 1 hydrochloride Chemical Structure
  23. GC34131 Protein kinase inhibitors 1 Protein kinase inhibitors 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM. Protein kinase inhibitors 1 Chemical Structure
  24. GC61217 Protein kinase inhibitors 1 hydrochloride Protein kinase inhibitors 1 hydrochloride is a potent HIPK2 inhibitor, with IC50s of 136 and 74 nM for HIPK1 and HIPK2, and a Kd of 9.5 nM for HIPK2. Protein kinase inhibitors 1 hydrochloride Chemical Structure
  25. GC11321 PRT-060318 novel Syk inhibitor PRT-060318 Chemical Structure
  26. GC25787 PRT-060318 2HCl PRT-060318 (PRT318) is a novel selective inhibitor of the Syk tyrosine kinase with an IC50 of 4 nM, as an approach to HIT treatment. PRT-060318 2HCl Chemical Structure
  27. GC31819 PRT062607 (P505-15) PRT062607 (P505-15)(P505-15; PRT-2607; BIIB-057) is a highly specific and potent inhibitor of Syk with IC50 of 1-2 nM; >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70. PRT062607 (P505-15) Chemical Structure
  28. GC10499 PRT062607 Hydrochloride PRT062607 Hydrochloride Chemical Structure
  29. GC65335 PTC299 PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies. PTC299 Chemical Structure
  30. GC32733 Pyrotinib (SHR-1258) Pyrotinib (SHR-1258) (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Pyrotinib (SHR-1258) Chemical Structure
  31. GC32989 Pyrotinib dimaleate (SHR-1258 dimaleate) Pyrotinib dimaleate (SHR-1258 dimaleate) (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively. Pyrotinib dimaleate (SHR-1258 dimaleate) Chemical Structure
  32. GC37047 Pz-1 Pz-1 is a potent RET and VEGFR2 inhibitor with IC50s of less than 1 nM for both wild type kinases. Pz-1 Chemical Structure
  33. GC17615 Quizartinib (AC220) Quizartinib (AC220) (AC220) is an orally active, highly selective and potent second-generation type II FLT3 tyrosine kinase inhibitor, with a Kd of 1.6 nM. Quizartinib (AC220) inhibits wild-type FLT3 and FLT3-ITD autophosphorylation in MV4-11 cells with IC50s of 4.2 and 1.1 nM, respectively. Quizartinib (AC220) can be linked to the VHL ligand via an optimized linker to form a PROTAC FLT3 degrader. Quizartinib (AC220) induces apoptosis. Quizartinib (AC220) Chemical Structure
  34. GC33874 R112 A Syk inhibitor R112 Chemical Structure
  35. GC12857 R1530 A multi-kinase inhibitor R1530 Chemical Structure
  36. GC16796 R406 SYK inhibitor,potent and ATP-competitive R406 Chemical Structure
  37. GC15658 R406(free base) Syk inhibitor R406(free base) Chemical Structure
  38. GC17618 R428 R428 (R428) is a potent and selective inhibitor of Axl with an IC50 of 14 nM. R428 Chemical Structure
  39. GC11811 R788 disodium R788 disodium (R788 Disodium) is the oral prodrug of the active compound R406. R788 disodium Chemical Structure
  40. GC15709 R788 disodium hexahydrate Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406. R788 disodium hexahydrate Chemical Structure
  41. GC33271 R916562 R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis. R916562 Chemical Structure
  42. GC11140 Radotinib(IY-5511) Bcr-Abl tyrosine kinase inhibitor Radotinib(IY-5511) Chemical Structure
  43. GC15818 RAF265 Multiple intracellular kinases inhibitor RAF265 Chemical Structure
  44. GC19534 Ramucirumab

    Ramucirumab is a fully human monoclonal antibody (IgG1).

     Ramucirumab Chemical Structure
  45. GC44806 Ras Inhibitory Peptide Son of sevenless homolog 1 (Sos1) is a guanine nucleotide exchange factor (GEF) that directs the exchange of Ras-GDP to Ras-GTP by binding to SH3 domains of the growth factor receptor-bound protein 2 (Grb2), leading to the activation of ERK. Ras Inhibitory Peptide Chemical Structure
  46. GC10111 Regorafenib A multi-kinase inhibitor Regorafenib Chemical Structure
  47. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride Chemical Structure
  48. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate Chemical Structure
  49. GC40213 Regorafenib-13C-d3 Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib-13C-d3 Chemical Structure
  50. GC64895 Regorafenib-d3 Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor. Regorafenib-d3 Chemical Structure
  51. GC19362 Repotrectinib TPX-0005 is a potent ALK/ROS1/TRK inhibitor, with IC50 of 5.3 nM, 1.01 nM, 1.26 nM and 1.08 nM for SRC, WT ALK, ALK G1202R and ALK L1196M, respectively. Repotrectinib Chemical Structure
  52. GC67917 RET-IN-7 RET-IN-7 Chemical Structure
  53. GC41467 Reveromycin D Reveromycin D is a bacterial metabolite originally isolated from Streptomyces. Reveromycin D Chemical Structure
  54. GC62341 Rezivertinib Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity. Rezivertinib Chemical Structure
  55. GC12038 RG 13022 EGFR tyrosine kinase inhibitor RG 13022 Chemical Structure
  56. GC10217 RG-14620 inhibitor of epidermal growth factor (EGF) receptor kinase RG-14620 Chemical Structure
  57. GN10784 Rhoifolin Rhoifolin Chemical Structure
  58. GC69817 Rilotumumab

    Rilotumumab (AMG 102) is a monoclonal antibody that targets the hepatocyte growth factor (HGF), inhibiting HGF/MET-driven signaling. Rilotumumab has anti-tumor activity and is being studied for use in castration-resistant prostate cancer (CRPC) and solid tumors.

     Rilotumumab Chemical Structure
  59. GC37538 Ripretinib Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis. Ripretinib Chemical Structure
  60. GC40547 RK-20448 RK-20448 is an ATP-competitive inhibitor of Lck, Src, KDR/VEGF2R, and Tie-2 (IC50s = 0.24, 1.19, 10.74, and 5.85 μM, respectively). RK-20448 Chemical Structure
  61. GC31701 RK-24466 (KIN 001-51) RK-24466 (KIN 001-51) (KIN 001-51) is a potent and selective Lck inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively. RK-24466 (KIN 001-51) Chemical Structure
  62. GC17622 Ro 08-2750

    antagonist of nerve growth factor (NGF)

     Ro 08-2750 Chemical Structure
  63. GC15466 RO9021 Syk inhibitor RO9021 Chemical Structure
  64. GC69825 Robatumumab

    Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor 1 receptor) antibody. Robatumumab has anti-tumor activity and anti-cancer cell proliferation activity. Robatumumab can be used for research on osteosarcoma and Ewing's sarcoma.

     Robatumumab Chemical Structure
  65. GC19154 Roblitinib Roblitinib (FGF-401) is a 1,8-naphthyridine pyridine derivative Roblitinib Chemical Structure
  66. GC33061 Rociletinib hydrobromide (CO-1686 (hydrobromide)) Rociletinib hydrobromide (CO-1686 (hydrobromide)) (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively. Rociletinib hydrobromide (CO-1686 (hydrobromide)) Chemical Structure
  67. GC34067 Rogaratinib (BAY1163877) Rogaratinib (BAY1163877) (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib (BAY1163877) Chemical Structure
  68. GC37556 ROR agonist-1 ROR agonist-1 is a potent and orally bioavailable inverse agonist of the retinoic acid receptor-related orphan receptor C2 (RORC2), inhibition of IL-17A production from human primary TH 17 cells with a pIC50 of 7.5. ROR agonist-1 Chemical Structure
  69. GC69830 RORγt agonist 3

    RORγt agonist 2 is an effective RORγt activator. It promotes Th17 cell differentiation, increases pro-inflammatory cytokine levels, and enhances lymphocyte cytotoxicity. RORγt agonist 2 inhibits the production of regulatory T cells, thereby suppressing immune responses (extracted from patent WO2021136326A1, compound 23).

     RORγt agonist 3 Chemical Structure
  70. GC68411 RORγt Inverse agonist 10 RORγt Inverse agonist 10 Chemical Structure
  71. GC62349 RORγt inverse agonist 13 RORγt inverse agonist 13 (Compound 3i) is a potent, orally active and selective RORγt inverse agonist, with improved drug-like properties, with an IC50 of 63.8 nM. RORγt inverse agonist 13 Chemical Structure
  72. GC65953 RORγt inverse agonist 23 RORγt inverse agonist 23 is a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist. RORγt inverse agonist 23 Chemical Structure
  73. GC37557 RORγt Inverse agonist 3 RORγt Inverse agonist 3 Chemical Structure
  74. GC62623 RORγt Inverse agonist 6 RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 Chemical Structure
  75. GC10517 Rp-8-bromo-Cyclic GMPS (sodium salt) cGMP-dependent protein kinase (cGK) inhibitor Rp-8-bromo-Cyclic GMPS (sodium salt) Chemical Structure
  76. GC10706 Rp-8-pCPT-Cyclic GMPS (sodium salt) GMP-dependent protein kinases (cGKs) inhibitor Rp-8-pCPT-Cyclic GMPS (sodium salt) Chemical Structure
  77. GC14779 RR-src Tyrosine kinase substrate peptide RR-src Chemical Structure
  78. GC37568 RTC-5 RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling. RTC-5 Chemical Structure
  79. GC38580 RU-301 RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 Chemical Structure
  80. GC64385 RU-302 RU-302 is a pan TAM inhibitor that blocks the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks Gas6-inducible Axl receptor activation with a low micromolar IC50in cell assays, and suppresses lung cancer tumor growth. RU-302 Chemical Structure
  81. GC69843 Ruserontinib

    Ruserontinib (SKLB1028) is an orally active inhibitor of EGFR, FLT3, and Abl kinases with an IC50 value of 55 nM against human FLT3. It has anti-tumor activity.

     Ruserontinib Chemical Structure
  82. GC63332 S116836 S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies. S116836 Chemical Structure
  83. GC65155 S18-000003 S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 Chemical Structure
  84. GC19317 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. S49076 Chemical Structure
  85. GC25881 S961 S961 is a biosynthetic insulin receptor antagonist that inhibits cellular proliferation and colony formation in breast tumour cells. S961 Chemical Structure
  86. GC61550 S961 acetate S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively. S961 acetate Chemical Structure
  87. GC39189 S961 TFA S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively. S961 TFA Chemical Structure
  88. GC41626 Sappanone A

    Sappanone A is a homoisoflavanone with strong antioxidant and anti-inflammatory activities.

     Sappanone A Chemical Structure
  89. GC33189 SAR125844 SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays. SAR125844 Chemical Structure
  90. GC12586 SAR131675

    VEGFR3 inhibitor,selective and ATP-competitve

     SAR131675 Chemical Structure
  91. GC15197 Saracatinib (AZD0530) Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases. Saracatinib (AZD0530) Chemical Structure
  92. GC19321 Savolitinib Savolitinib (AZD6094) ia highly potent and selective c-Met inhibitor with an IC50 of 5 nM. Savolitinib Chemical Structure
  93. GC48070 SB-431542 (hydrate) Inhibitor of receptors ALK4, ALK5, and ALK7 SB-431542 (hydrate) Chemical Structure
  94. GC12064 SB1317 A multi-kinase inhibitor SB1317 Chemical Structure
  95. GC14349 SB525334 (TGF-beta1) receptor inhibitor SB525334 Chemical Structure
  96. GC19108 SCR-1481B1 SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor. SCR-1481B1 Chemical Structure
  97. GN10633 Scutellarein Scutellarein Chemical Structure
  98. GC37620 Secretin, canine Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine Chemical Structure
  99. GC68430 Selatinib Selatinib Chemical Structure
  100. GC32808 Selitrectinib (LOXO-195) Selitrectinib (LOXO-195) (LOXO-195) is a next-generation TRK kinase inhibitor, with IC50s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively. Selitrectinib (LOXO-195) Chemical Structure
  101. GC33192 Selpercatinib A RET kinase inhibitor Selpercatinib Chemical Structure

Items 801 to 900 of 1115 total

per page
  2. 7
  3. 8
  4. 9
  5. 10
  6. 11

Set Descending Direction